Start and continue with Avastin in MCRC for proven OS

In the first-line Study 2107: Median OS of 20.3 vs 15.6 months with Avastin plus IFL vs IFL alone (HR=0.66 [95% CI, 0.54–0.81], P<0.001).[1,3]
In the first- through second-line TML study*: Median OS of 11.2 vs 9.8 months with Avastin plus fluoropyrimidine-based chemotherapy vs fluoropyrimidine-based chemotherapy alone (HR=0.81 [95% CI, 0.69–0.94], P=0.0057).[1]

MCRC=metastatic colorectal cancer; OS=overall survival; IFL=5-fluorouracil/leucovorin/irinotecan; HR=hazard ratio; CI=confidence interval.
*TML=Treatment through Multiple Lines (first and second line).
Chemotherapy combinations included either an irinotecan- or oxaliplatin-containing regimen.[1]

Insurer/payer policies are subject to change. The completion and submission of coverage or reimbursement-related documentation are the responsibility of the patient and the healthcare provider. Genentech makes no guarantee concerning coverage or reimbursement for any service or item. Inclusion of a plan or product is not intended to imply a recommendation of a particular plan or product. Coverage percentage shown is a weighted average based on national patients treated for Avastin.
§As of 01/01/2021, national coverage for Avastin is 85%+.